Silvio E Inzucchi

Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial

O. Vedin, Stuart Pocock, Christoph Wanner, 2024, Cardiovascular diabetology.

Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease

J. Rajpura, Yuanjie Liang, Josh Noone, 2023, Cardiovascular Diabetology.